Eluminex Biosciences develops full-length triple helix recombinant human type III collagen and trispecific recombinant humanized fusion antibodies to enhance dermal aesthetics and treat retinal diseases. The company addresses the need for effective therapies in regenerative medicine and vision-threatening conditions, aiming to improve patient outcomes through its proprietary protein therapeutics.
Funding
Funding not disclosed
Founders
Product
Problem
The fields of dermal aesthetics and ophthalmology face challenges in effectively addressing skin quality and vision-threatening conditions. Current treatments may lack the necessary efficacy in promoting skin elasticity or preventing vision loss due to retinal diseases.
Solution
Eluminex Biosciences is developing protein therapeutics, including full-length triple helix recombinant human type III collagen for dermal aesthetics and trispecific recombinant humanized fusion antibodies for retinal diseases. Their recombinant human type III collagen aims to improve skin quality by providing elastic rebound, while their antibodies target vision-threatening conditions in the field of ophthalmology. Eluminex operates a GMP manufacturing facility for its recombinant human type III collagen to support clinical programs in dermal aesthetics, tissue regeneration, and ophthalmics, specifically a biosynthetic cornea program. The company aims to develop first-in-class or best-in-class protein therapeutics to enhance patient outcomes in regenerative medicine, aesthetics, and vision-threatening diseases.
Target Audience
The primary target audience includes individuals seeking advanced dermal facial aesthetics treatments and patients with vision-threatening conditions such as retinal diseases.
Features
- Full-length triple helix recombinant human type III collagen for improved skin elasticity
- Trispecific recombinant humanized fusion antibodies for targeted treatment of retinal diseases
- GMP manufacturing facility for recombinant human type III collagen production
- Development of protein therapeutics for dermal aesthetics and tissue regeneration
- Pipeline programs focused on vision-threatening diseases